Cargando…

Hyperglycemia, glucocorticoid therapy, and outcome of COVID-19

Detalles Bibliográficos
Autores principales:	Morieri, Mario Luca, Fadini, Gian Paolo, Boscari, Federico, Fioretto, Paola, Maran, Alberto, Busetto, Luca, Crepaldi, Maria Cristina, Vedovato, Monica, Bonora, Benedetta Maria, Selmin, Elisa, Arcidiacono, Gaetano, Pinelli, Silvia, Farnia, Filippo, Falaguasta, Daniele, Russo, Lucia, Voltan, Giacomo, Mazzocut, Sara, Costantini, Giorgia, Ghirardini, Francesca, Tresso, Silvia, Cattelan, Anna Maria, Vianello, Andrea, Vettor, Roberto, Avogaro, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494492/ https://www.ncbi.nlm.nih.gov/pubmed/32949651 http://dx.doi.org/10.1016/j.diabres.2020.108449

Ejemplares similares

Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration
por: Fadini, Gian Paolo, et al.
Publicado: (2020)

In hospital risk factors for acute kidney injury and its burden in patients with Sars-Cov-2 infection: a longitudinal multinational study
por: Morieri, Mario Luca, et al.
Publicado: (2022)

Glycemic control after switching to faster aspart in adults with type 1 diabetes
por: Fadini, G. P., et al.
Publicado: (2022)

Time-series analysis of multidimensional clinical-laboratory data by dynamic Bayesian networks reveals trajectories of COVID-19 outcomes
por: Longato, Enrico, et al.
Publicado: (2022)

Improved prediction of long-term kidney outcomes in people with type 2 diabetes by levels of circulating haematopoietic stem/progenitor cells
por: Bonora, Benedetta Maria, et al.
Publicado: (2023)

Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Why diabetes outpatient clinics should not close during pandemic crises
por: Fadini, G. P., et al.
Publicado: (2021)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Response to Chia Siang Kow and colleagues
por: Avogaro, Angelo, et al.
Publicado: (2022)

Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care
por: Morieri, Mario Luca, et al.
Publicado: (2022)

Prevalence and impact of diabetes among people infected with SARS-CoV-2
por: Fadini, G. P., et al.
Publicado: (2020)

Current smoking is not associated with COVID-19
por: Rossato, Marco, et al.
Publicado: (2020)

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
por: Bonora, Benedetta Maria, et al.
Publicado: (2021)

Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study
por: Morieri, M. L., et al.
Publicado: (2023)

Putative circulating adipose tissue-derived stem cells, obesity, and metabolic syndrome features
por: Bonora, B. M., et al.
Publicado: (2023)

Managing diabetes in diabetic patients with COVID: where do we start from?
por: Avogaro, Angelo, et al.
Publicado: (2021)

Comparative effectiveness of exenatide once‐weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta‐analysis of observational studies
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Effectiveness of adding alarms to flash glucose monitoring in adults with type 1 diabetes under routine care
por: Boscari, Federico, et al.
Publicado: (2022)

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
por: Bonora, Benedetta Maria, et al.
Publicado: (2019)

Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis
por: Bonora, B. M., et al.
Publicado: (2021)

Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes
por: Morieri, Mario Luca, et al.
Publicado: (2021)

Cardiopulmonary exercise testing in patients with moderate-severe obesity: a clinical evaluation tool for OSA?
por: Vecchiato, Marco, et al.
Publicado: (2021)

Adipogenic progenitors in different organs: Pathophysiological implications
por: Favaretto, Francesca, et al.
Publicado: (2021)

DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes
por: Fadini, Gian Paolo, et al.
Publicado: (2017)

Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives
por: Boscari, Federico, et al.
Publicado: (2021)

Renal structure in type 2 diabetes: facts and misconceptions
por: Di Vincenzo, Angelo, et al.
Publicado: (2020)

Fixed versus flexible combination of GLP‐1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study
por: Morieri, Mario Luca, et al.
Publicado: (2019)

p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Correction to: Physicians’ misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes
por: Morieri, Mario Luca, et al.
Publicado: (2022)

Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
por: Avogaro, Angelo, et al.
Publicado: (2016)

Obesity management: at the forefront against disease stigma and therapeutic inertia
por: Busetto, Luca, et al.
Publicado: (2021)

Improved long-term cardiovascular outcomes after intensive versus standard screening of diabetic complications: an observational study
por: Morieri, Mario Luca, et al.
Publicado: (2019)

Glycaemic Control Achieves Sustained Increases of Circulating Endothelial Progenitor Cells in Patients Hospitalized for Decompensated Diabetes: An Observational Study
por: Bonora, Benedetta Maria, et al.
Publicado: (2022)

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
por: Fadini, Gian Paolo, et al.
Publicado: (2017)

Practical Considerations for the Management of Cushing's Disease and COVID-19: A Case Report
por: Beretta, Federica, et al.
Publicado: (2020)

Cardiometabolic indices predict hypogonadism in male patients with type 2 diabetes
por: Caretta, N., et al.
Publicado: (2022)

Higher Levels of C-Reactive Protein and Ferritin in Patients with Overweight and Obesity and SARS-CoV-2-Related Pneumonia
por: Bettini, Silvia, et al.
Publicado: (2021)

Performance assessment across different care settings of a heart failure hospitalisation risk-score for type 2 diabetes using administrative claims
por: Guazzo, Alessandro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_26k3def6fb1fr0ce69npfk7dkg